Greg Jones
Company: Pfizer
Job title: Principal Scientist
Seminars:
Multi-Omics Data Integration Reveals New Targets In RAS-Mutant Cancers Resistant to KRASG12C Inhibition 3:30 pm
In Vivo CRIPSR screens in RAS mutant cell lines models reveal new vulnerabilities for ERK/MAPK addicted cancers KRASG12Ci Resistant cell lines models can be leveraged to reveal treatment emergent vulnerabilities in these cancers Co-Targeting of the RAS and Hippo pathway might provide a rationale therapeutic approach to overcome resistance to RAS targeted therapies with Biomarker…Read more
day: Day Two Track E
Intrinsic & Adaptive Resistance 3:00 pm
day: Pre-Conference Day Track F